IONS
NasdaqGSIonis Pharmaceuticals, Inc.
Price
Key statistics
Insider activity
SEC EDGAR ↗Showing 20 recent filings. 16 other (grants, option exercises, gifts, tax withholding) are listed below but excluded from buy/sell flow.
| Insider | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|
Reikes Peter N Director | Grant / award | 3.4K | $0.00 | — | 2026-07-15 |
HANTSON LUDWIG Director | Grant / award | 3.4K | $0.00 | — | 2026-07-15 |
HERMAN JOAN E Director | Option exercise | 5.22K | $0.00 | — | 2026-07-15 |
HERMAN JOAN E Director | Option exercise | 5.22K | $0.00 | — | 2026-07-15 |
BERTHELSEN SPENCER R Director | Option exercise | 5.22K | $0.00 | — | 2026-07-15 |
BERTHELSEN SPENCER R Director | Option exercise | 5.22K | $0.00 | — | 2026-07-15 |
BENNETT C FRANK EVP, Chief Scientific Officer | Sell (open market) | 5.54K | $83.58 | $462,693.34 | 2026-07-07 |
BENNETT C FRANK EVP, Chief Scientific Officer | Code J | 15K | $0.00 | — | 2026-07-07 |
BENNETT C FRANK EVP, Chief Scientific Officer | Sell (open market) | 15K | $85.46 | $1,281,930.00 | 2026-07-07 |
BENNETT C FRANK EVP, Chief Scientific Officer | Code J | 15K | $0.00 | — | 2026-07-07 |
Diaz Allene M. Director | Option exercise | 10.11K | $47.11 | $476,329.21 | 2026-07-07 |
Diaz Allene M. Director | Sell (open market) | 10.11K | $85.42 | $863,637.13 | 2026-07-07 |
Diaz Allene M. Director | Option exercise | 10.11K | $0.00 | — | 2026-07-07 |
Kordasiewicz Holly B. EVP, Chief Development Officer | Sell (open market) | 362 | $84.30 | $30,516.60 | 2026-07-07 |
YANG MICHAEL J. Director | Grant / award | 5.37K | $0.00 | — | 2026-07-01 |
YANG MICHAEL J. Director | Grant / award | 2.3K | $0.00 | — | 2026-07-01 |
LOSCALZO JOSEPH Director | Grant / award | 5.37K | $0.00 | — | 2026-07-01 |
LOSCALZO JOSEPH Director | Grant / award | 2.3K | $0.00 | — | 2026-07-01 |
HERMAN JOAN E Director | Grant / award | 5.37K | $0.00 | — | 2026-07-01 |
HERMAN JOAN E Director | Grant / award | 2.3K | $0.00 | — | 2026-07-01 |
Source: SEC EDGAR Forms 4/4A (CIK 874015). Click an insider to open the original filing.
Social sentiment
Volume-weighted across live social sources
$IONS Cathie Wood Just Bet Big on This Biotech Stock | The Motley Fool https://share.google/jgStgeOEggcd5PL0n
Trying to warm up to $IONS on the selloff, but red flag for me is that the CEO seems to dismiss competition from $ARWR's Redemplo at every turn Multiple calls, same theme (focusing on Tryngolza launch, not what others are doing) Respect the emphasis on execution, but still...
$IONS The Phase 3 ATTR setback with AZN hit the stock hard, wiping out about $4.63B in market value. But the estimated fair value impact was closer to $3B, creating a gap. ~$5B peak sales potential from owned products ~$1.35B peak royalty revenue Zero net debt At roughly 3x peak sales, the valuation looks interesting if execution continues. The big question: opportunity or value trap? What’s your view on $IONS?
$IONS they’re really suppressing this stock and just won’t let it up.
$IONS green incoming. Gl all.
$IONS Hey batted, I just loaded up. Now make me rich.
$IONS Wtf man… just non-stop selling everyday.
$IONS in
$IONS big bounce tomorrow. Gl all.
$IONS Wow...watching.
$IONS Cathie Wood’s ARK Invest acquired 66,277 shares of Ionis Pharmaceuticals (IONS) through the ARK Genomic Revolution ETF (ARKG) in July 2026, marking a fresh round of buying in the biotechnology stock as part of a broader reshuffle of healthcare and tech portfolios.The recent acquisition by Wood's ARK Invest totaled about $3.86 million, bringing fresh capital to Ionis alongside investments in other biotech innovators like Prime Medicine and Beam Therapeutics. Prior to this, her funds also reported picking up $8.8 million of IONS in an earlier July reshuffle.
$IONS Manifesting the bounce. Chip in guys.
Latest news
Cathie Wood Just Bet Big on This Biotech Stock
Ionis to hold second quarter 2026 financial results webcast
Biogen Slumps As Alzheimer's Study Leaves 'More Questions Than Answers'
Morgan Stanley Raises its Price Target on Alnylam (ALNY)
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
Ionis Partner Biogen Presents Phase 2 CELIA Data at AAIC Demonstrating Meaningful Clinical Outcomes and Robust Tau Reduction with Diranersen in Early Alzheimer’s Disease
Biogen Stock Is Upgraded to Buy Ahead of Key Alzheimer’s Drug Study Details
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions
Ionis Doses First Participant in Phase 1-2 Trial of Dravet Syndrome Therapy
Ionis doses first participant in Phase 1-2 ASCEND study of ION337 in Dravet syndrome
Get insider-buy alerts
Free weekly digest of the most notable SEC insider purchases — plus early access to real-time alerts on your watchlist.